You may be aware of the funding chasm that novel drug candidates must cross in order to make it to US markets. Most drugs never see the light of day because of this multi-billion dollar hurdle and the rigorous testing that follows. In an effort to do this job more efficiently, the FDA has made slight modifications, which I'll try to blog about in greater detail at some point. A new study in the New England Journal of Medicine suggests that quicker may not be safer.
I have not read this yet, but USAtoday has an article comparing the presidential candidates' health care plans.
0 comments:
Post a Comment